Swedbank AB Purchases 7,934 Shares of Stryker Corporation $SYK

Swedbank AB boosted its position in Stryker Corporation (NYSE:SYK) by 6.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 129,027 shares of the medical technology company’s stock after acquiring an additional 7,934 shares during the period. Swedbank AB’s holdings in Stryker were worth $45,349,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SYK. United Financial Planning Group LLC bought a new position in shares of Stryker in the third quarter valued at approximately $27,000. Strive Asset Management LLC bought a new position in shares of Stryker in the third quarter valued at approximately $30,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker in the third quarter valued at approximately $34,000. Copia Wealth Management lifted its holdings in shares of Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in Stryker during the fourth quarter worth $40,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $294.49 on Friday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The business’s fifty day simple moving average is $340.37 and its 200 day simple moving average is $355.17. Stryker Corporation has a 12 month low of $289.91 and a 12 month high of $404.87. The firm has a market capitalization of $112.78 billion, a P/E ratio of 34.08, a price-to-earnings-growth ratio of 1.84 and a beta of 0.80.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the prior year, the business earned $2.84 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analyst Ratings Changes

A number of analysts recently commented on the company. Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday, May 1st. Jefferies Financial Group reiterated a “buy” rating and set a $465.00 price target on shares of Stryker in a report on Wednesday, March 4th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Piper Sandler reiterated an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Finally, Evercore set a $355.00 price target on Stryker in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.